Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
32
RGBP Quote, Financials, Valuation and Earnings
Last price:
$0.0100
Seasonality move
:
32.11%
Day range:
$0.0090 - $0.0104
52-week range:
$0.0038 - $0.1169
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.76x
P/B ratio:
--
Volume:
120.1K
Avg. volume:
558.9K
1-year change:
-81.45%
Market cap:
$563.4K
Revenue:
$236.6K
EPS (TTM):
-$0.15
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Regen Biopharma, Inc. has -- downside to fair value with a price target of -- per share.
RGBP vs. S&P 500
-
Over the past 5 trading days, Regen Biopharma, Inc. has overperformed the S&P 500 by 0.57% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Regen Biopharma, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Regen Biopharma, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Regen Biopharma, Inc. reported revenues of $59.1K.
Earnings Growth
-
Regen Biopharma, Inc. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Regen Biopharma, Inc. reported earnings per share of -$0.01.
Enterprise value:
1.6M
EV / Invested capital:
--
Price / LTM sales:
0.76x
EV / EBIT:
--
EV / Revenue:
6.75x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-3.71x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-770.75%
Net Income Margin (TTM):
-578.96%
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
-69.04%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2025-06-30 | |
| Income Statement | ||||||
| Revenue | $236.6K | $236.6K | $236.6K | $59.1K | $59.1K | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$725.6K | -$390.9K | -$300.9K | -$108K | -$40.8K | |
| EBITDA | -$725.6K | -$390.9K | -$300.9K | -$108K | -$40.8K | |
| Diluted EPS | $0.18 | -$0.09 | -$0.20 | -$0.02 | -$0.01 | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $379.1K | $440.3K | $62.6K | $152.4K | $179.1K | |
| Total Assets | $1.4M | $689.7K | $285.2K | $170.2K | $196.8K | |
| Current Liabilities | $13.8M | $9M | $5.3M | $5.3M | $6M | |
| Total Liabilities | $13.8M | $9M | $5.3M | $5.3M | $6M | |
| Total Equity | -$12.4M | -$8.3M | -$5M | -$5.2M | -$5.8M | |
| Total Debt | $2.4M | $1.6M | $509.9K | $718.1K | $266.3K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2025-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$535.8K | -$567.7K | -$430.9K | -$172.6K | -$56K | |
| Cash From Investing | $25K | -- | -- | -- | -- | |
| Cash From Financing | $400.5K | $628.8K | $370.8K | $156.3K | $56K | |
| Free Cash Flow | -$535.8K | -$567.6K | -$430.9K | -$172.6K | -$56K | |
RGBP
Sector
Market Cap
$563.4K
--
Price % of 52-Week High
8.73%
--
Dividend Yield
0%
--
Shareholder Yield
-5.87%
--
1-Year Price Total Return
-81.46%
--
Beta (5-Year)
3.056
--
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.0096
200-day SMA
Sell
Level
$0.0375
Bollinger Bands (100)
Sell
Level
0.008 - 0.028
Chaikin Money Flow
Buy
Level
1.7M
20-day SMA
Buy
Level
$0.0096
Relative Strength Index (RSI14)
Buy
Level
50.7041
ADX Line
Buy
Level
20.9249
Williams %R
Neutral
Level
-37.2549
50-day SMA
Sell
Level
$0.0111
MACD (12, 26)
Buy
Level
0.0025
25-day Aroon Oscillator
Sell
Level
-16
On Balance Volume
Neutral
Level
1.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-223.3815)
Sell
CA Score
(Annual)
Level (-101.7782)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (1)
Sell
Ohlson Score
Level (256.6004)
Sell
Piotroski F Score
(Annual)
Level (3)
Buy
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Regen Biopharma, Inc. is a biotechnology company, which engages in the business of developing regenerative medical applications and advancing novel technologies through pre-clinical and Phase I and II clinical trials. It also focuses on mRNA and small molecule therapies for treating cancer and autoimmune disorders. The company was founded on April 24, 2012 and is headquartered in La Mesa, CA.
Stock Forecast FAQ
In the current month, RGBP has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The RGBP average analyst price target in the past 3 months is --.
-
Where Will Regen Biopharma, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Regen Biopharma, Inc. share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Regen Biopharma, Inc.?
Analysts are divided on their view about Regen Biopharma, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Regen Biopharma, Inc. is a Sell and believe this share price will rise from its current level to --.
-
What Is Regen Biopharma, Inc.'s Price Target?
The price target for Regen Biopharma, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is RGBP A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Regen Biopharma, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of RGBP?
You can purchase shares of Regen Biopharma, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Regen Biopharma, Inc. shares.
-
What Is The Regen Biopharma, Inc. Share Price Today?
Regen Biopharma, Inc. was last trading at $0.0100 per share. This represents the most recent stock quote for Regen Biopharma, Inc.. Yesterday, Regen Biopharma, Inc. closed at $0.0102 per share.
-
How To Buy Regen Biopharma, Inc. Stock Online?
In order to purchase Regen Biopharma, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get RGBP Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
RGBP
Sector
P/E ratio
--
--
PEG ratio
0.00x
--
P/B ratio
--
--
Price / LTM sales
0.76x
--
Growth Metrics
RGBP
Sector
Revenue growth
--
--
Earnings growth
33.33%
--
Revenue (5-year growth)
16.55%
--
Earnings forecast
--
--
Profitability
RGBP
Sector
Profitability FY 2024
--
--
Return on invested capital
--
--
Return on assets
-770.75%
--
Return on equity
--
--
Earnings Date
Last Earnings Date
Dec
26
Next Earnings Date
Dec
26
Estimated Next Earnings Date
Mar
27
Balance Sheet
RGBP
Sector
Total cash
$1.8K
--
Short term investments
--
--
Total assets
$161.1K
--
Long term debt
$1M
--
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
